{"organizations": [], "uuid": "dd83cb0e57494be5e8e8a7a5084df55ac8df08d3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180307.html", "section_title": "Archive News &amp; Video for Wednesday, 07 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-us-fda-continues-to-monitor-advers/brief-u-s-fda-continues-to-monitor-adverse-events-connected-with-essure-idUSFWN1QP0VZ", "country": "US", "domain_rank": 408, "title": "BRIEF-U.S. FDA Continues To Monitor Adverse Events Connected With Essure", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.716, "site_type": "news", "published": "2018-03-08T03:56:00.000+02:00", "replies_count": 0, "uuid": "dd83cb0e57494be5e8e8a7a5084df55ac8df08d3"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-us-fda-continues-to-monitor-advers/brief-u-s-fda-continues-to-monitor-adverse-events-connected-with-essure-idUSFWN1QP0VZ", "ord_in_thread": 0, "title": "BRIEF-U.S. FDA Continues To Monitor Adverse Events Connected With Essure", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "u.s. food and drug administration", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 7 (Reuters) - U.S. Food And Drug Administration:\n* U.S. FDA SAYS AT CURRENT TIME, IS ACTIVELY EVALUATING A COLLECTION OF NEW MEDICAL DEVICE REPORTS SUBMITTED TO FDA ON ESSURE DEVICE\n* U.S FDA SAYS OF THE NEARLY 12,000 REPORTS RECEIVED IN 2017 FOR ESSURE, THE MAJORITY WERE SENT TO FDA IN LAST QUARTER OF THE YEAR\n* U.S. FDA SAYS CONTINUES TO BELIEVE THAT ESSURE MAY BE APPROPRIATE FOR SOME WOMEN BASED ON FDA’S CURRENT INFORMATION\n* U.S. FDA SAYS ALSO RECOGNIZES THAT “SERIOUS PROBLEMS” HAVE BEEN ASSOCIATED WITH USE OF ESSURE\n* U.S. FDA SAYS CONTINUING TO MONITOR ADVERSE EVENTS CONNECTED WITH ESSURE REPORTED TO FDA’S DATABASE, AS WELL AS OTHER DATA SOURCES Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-08T03:56:00.000+02:00", "crawled": "2018-03-08T17:37:09.027+02:00", "highlightTitle": ""}